chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually have chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable & treatable disease.

Drug Information

Indication: Regular treatment of COPD including chronic bronchitis & emphysema. Accuhaler Regular treatment of asthma ...

Indication: Maintenance bronchodilator treatment for symptomatic relief of COPD. Add-on maintenance bronchodilator treatme...

Indication: Maintenance treatment in patients w/ chronic obstructive pulmonary disease (COPD).

Indication: Asthma: Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting &beta...

Ultibro Breezhaler
glycopyrronium bromide + indacaterol maleate

Indication: Maintenance bronchodilator treatment to relieve symptoms & reduce exacerbations in adult patients w/ COPD.

Indication: Bronchodilator for maintenance treatment of bronchospasm associated w/ COPD including chronic bronchitis &...

Indication: Bronchodilator for maintenance treatment of bronchospasm, associated w/ COPD, including chronic bronchitis, em...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Dosage: Symptomatic treatment of acute asthma episodes 1 puff stat. If breathing has not improved after 5 min, a 2nd p

1  /  14
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Nov 2017
Active and passive smoking are associated with atopic dermatitis, a new study from Korea reveals.
Pank Jit Sin, 09 Aug 2018

Atezolizumab (Tecentriq®, Roche) a programmed death-ligand 1 (PD-L1) inhibitor, is now approved for the treatment of patients with metastatic non-small cell lung cancer who have diseases progression during or following a platinum-containing therapy.

Pearl Toh, 19 Apr 2017
Almost half of secondary school children who had been diagnosed with asthma had suboptimal asthma control, yet over half of those surveyed did not use their inhalers as prescribed, a recent study found.